A comparative analysis of acute-phase proteins as inflammatory biomarkers in preclinical toxicology studies: Implications for preclinical to clinical translation

Toxicologic Pathology

Volumn 37, Issue 1, 2009, Pages 28-33

  Watterson, Claire ^a   Lanevschi, Anne ^a   Horner, Judith ^a   Louden, Calvert ^b  

^a ASTRAZENECA   (United Kingdom)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Biomarkers; Inflammation; Preclinical safety assessment risk management

Indexed keywords

ACUTE PHASE PROTEIN; BINDING PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HAPTOGLOBIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; LIPOLYSACCARIDE BINDING PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCALCITONIN; SERUM AMYLOID A; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; XENOBIOTIC AGENT;

BIOLOGICAL MONITORING; BLOOD CLOTTING; COMPARATIVE STUDY; CYTOKINE PRODUCTION; DIAGNOSTIC TEST; HEMOSTASIS; HUMAN; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; SCREENING TEST; SHOCK; SPECIES DIFFERENCE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VASCULAR ENDOTHELIUM; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DOG; DRUG SCREENING; METABOLISM; METHODOLOGY; MOUSE; RAT; TOXICITY TESTING;

ANIMALIA;

ACUTE-PHASE PROTEINS; ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DOGS; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; RATS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TOXICITY TESTS; XENOBIOTICS;

EID: 62749191497     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623308329286     Document Type: Review

References (32)

1. Aledort, LM (2003). Why thrombin generation? From bench to bedside. Pathophysiol Hemost Thromb, 33, 2-3.
2. Asakura, H, H Wada, K Okamoto, T Iba, T Uchiyama, Y Eguchi, K Kawasugi, S Koga, T Mayumi, K Koike, and S Gando (2006). Evaluation of hemostatic molecular markers for diagnosis of disseminated intravascular coagulation in patients with infections. Thromb Haem, 95, 282-287.
3. Cavaillon, JM, and D Annane (2006). Compartmentalisation of the inflammatory response in sepsis and SIRS. Review. J Endotoxin Res, 12, 151-170.
4. Cicala, C, and G Cirino (1998). Linkage between inflammation and coagulation: An update on the molecular basis of the crosstalk. Life Sci, 62, 1817-1824.
5. Collins, PW, LI Macchiavello, S Lewis, N Macartney, A Saayman, R Luddington, T Baglin, and G Findlay (2006). Global tests of hemostasis in criticially ill patients with severe sepsis syndrome compared to controls. Br J Haematol, 135, 220-227.
6. Conway, DSG, P Buggins, E Hughes, and EYH Lip (2004). Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol, 43, 2075-2082. (Pubitemid 38686805)
7. Fang, XM, S Schroder, A Hoeft, and F Stuber (1999). Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to sever sepsis. Crit Care Med, 27, 1330-1334.
8. Fisher, CJ, Jr, and SB Yan (2000). Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med, 28, S49-56.
9. Gando, S, S Nanzaki, S Sasaki, and O Kemmotsu (1998). Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb Hemost, 79, 1111-1115.
10. Garcia-Fernandez, N, R Montes, A Purroy, and E Rocha (2000). Hemostatic disturbances in patients with systemic inflammatory response syndrome and associated acute renal failure. Thromb Res, 100, 19-25.
11. Gentry, PA (1999). Acute phase proteins. In WF Loeb and FW Quimby (Eds.), The Clinical Chemistry of Laboratory Animals (pp. 336-398). Ann Arbor, MI: Taylor and Francis.
12. Gribble, EJ, PV Sivakumar, RA Ponce, and SD Hughes (2007). Toxicity as a result of immunostimulation by biologics. Expert Opin Drug Metab Toxicol, 3, 209-234.
13. Hemker, HC, S Wielders, H Kessels, and S Beguin (1993). Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Hemost, 70, 617-624.
14. Herzum, I, and H Renz (2008). Inflammatory markers in SIRS, sepsis and septic shock. Review. Curr Clin Chem, 15, 581-587.
15. Iba, T, S Gando, A Murata, S Kushimoto, D Saitoh, Y Eguchi, Y Ohtomo, K Okamoto, K Koseki, T Mayumi, T Ikeda, H Ishhikura, M Ueyama, Y Ogura, S Endo, and S Shimazaki (2007). Predicitng the severity of systemic inflammatory response syndrome (SIRS)-associated coagulopathy with hemostatic molecular markers and vascular endothelial injury markers. J Trauma, 63, 1093-1098.
16. International Conference for Harmonization (ICH) (2006). Guidance for industry. S8. Immunotoxic studies for human pharmaceuticals. Center for Drug Evaluation and Research, Food and Drug Administration, Office of Training and Communication. Division of Drug Information, HFD-240, Rockville, MD, USA.
17. Jinbo, T, S Hayashi, K Iguchi, M Shimizu, T Matsumoto, M Naiki, and S Yamamoto (1998). Development of monkey C-reactive protein (CRP) assay methods. Vet Immunol Immunopathol, 61, 195-202.
18. Kox, WJ, T Volk, SN Kox, and HD Volk (2004). Immunomodulatory therapies in sepsis. Intensive Care Med, 26, S124-28.
19. Lanevschi-Pietersma, A, C Bedard, and M Dunn (2003). D-dimer, TAT complex and FDPs measured in dogs with different systemic diseases. Vet Clin Pathol, 32, 225.
20. Mann, KG, S Butenas, and K Brummel (2003). The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol, 23, 17-25.
21. Mokart, D, M Merlin, A Sannini, JP Brun, JR Delpero, G Houvenaeghel, V Moutardier, and JL Blache (2005). Procalcitonin, interleukin 6 and systemic inflammatory response syndrome (SIRS): early markers of postoperative sepsis after major surgery. Br J Anaesth, 94, 767-773.
22. Murata, H, N Shimada, and M Yoshioka (2004). Current research on acute phase proteins in veterinary diagnosis: an overview. Vet J, 168, 28-40.
23. Myers, LA, JT Boyce, and RL Robison (1995). The tolerability and pharmacology of interleukin-6 administered in combination with GM-CSF or G-CSF in the rhesus monkey. Toxicol, 101, 156-166.
24. Oda, S, H Hirasawa, H Shiga, K Nakanishi, K Matsuda, and M Nakammua (2005). Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cytokine, 29, 169-175.
25. Ravanat, C, M Freund, F Dol, Y Cadroy, J Roussi, F Incardona, JP Maffrand, B Boneu, L Drouet, C Legrand, JM Herbert, and JP Cazenave (1995). Cross-reactivity of human molecular markers for detection of prethrombotic states in various animal species. Blood Coagul Fibrinolysis, 6, 446-455.
26. Ridker, PM (2001). Role of inflammatory biomarkers in prediction of coronary heart disease. Lancet, 358, 946-948.
27. Riedemann, NC, RF Guo, and PA Ward (2003). Novel strategies for the treatment of sepsis. Nat Med, 9, 517-524.
28. Sherwood, E, and T Toliver-Kinsky (2004). Mechanisms of the inflammatory response. Best Pract Anaesthesiol, 18, 385-405.
29. St Clair, EW (2008). The calm after the storm: lessons from the TGN1412 trial. J Clin Invest, 118, 1344-1347.
30. Van Veen, JJ, M Gatt, and M Makris (2008). Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol, 142, 889-903.
31. Watanabe, R, H Wada, Y Watanabe, M Sakakura, T Nakasaki, Y Mori, M Nishikawa, EC Gabazza, T Nobori, and H Shiku (2001). Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res, 104, 1-6.
32. Wattanathum, A, S Manocha, H Groshaus, JA Russell, and KR Walley (2005). Interleukin-10 haplotype associated with increased mortality in critically ill patients with sepsis from pneumonia but not in patients with extrapulmonary sepsis. Chest, 128, 1690-1698.